EUCTR2017-001420-21-DE进行中（未招募）1 期
A Phase 3, Twelve-week, Multi-Center, Multinational, Randomized, Double-Blind, Double-Dummy, Parallel Group Study to Determine the Efficacy, Safety and Tolerability of P2B001 Once Daily Compared to its Individual Components in Subjects With Early Parkinson’s Disease and to a Calibration Arm of Pramipexole ER.
相关药物
试验速览
- 阶段
- 1 期
- 状态
- 进行中（未招募）
- 入组人数
- 525
研究概览
简要总结
暂无简介。
研究设计
- 研究类型
- Interventional clinical trial of medicinal product
入排标准
- 性别
- All
入选标准
- •1.Subject is informed and given ample time and opportunity to think about his/her participation in this study and has given his/her written informed consent on an EC/IRB approved consent form.
- •2.Subject is willing and able to comply with all study requirements (protocol, clinic visits, procedures and medication administration).
- •3.Subject is male or female =35 years of age to =80 years of age at the time of enrollment
- •4.Subject has Parkinson's disease consistent with the UK Brain Bank Criteria and must have bradykinesia with sequence effect. If rest tremor does not exist must have prominent asymmetry of motor function.
- •5.Subject with disease duration less than 3 years since diagnosis
- •6.Subject has a H&Y stage score of < 3.
- •7.Subject has a MMSE score = 26.
- •8.Women of child-bearing potential (WOCBP)* must use a reliable method of contraception (e.g., oral contraceptive or long-term injectable or implantable hormonal contraceptive, double-barrier methods [such as condom plus diaphragm, condom plus spermicide foam, condom plus sponge], or intra-uterine devices) for the entire study duration, and must have a negative serum pregnancy test at Screening and negative urine pregnancy at baseline visit.
- •*WOCBP are defined as any female who has experienced menarche and who is NOT permanently sterile or postmenopaused. Postmenopausal is defined as 12 consecutive months with no menses without an alternative medical cause.
- •9.Subject was approved by a central Eligibility Monitoring Committee (EMC) based on suitability for the study, and his/her eligibility was confirmed by EMC signature on the Randomization Authorization Form (RAF).
- •Are the trial subjects under 18? no
- •Number of subjects for this age range:
- •F.1.2 Adults (18-64 years) yes
- •F.1.2.1 Number of subjects for this age range 262
- •F.1.3 Elderly (>=65 years) yes
- •F.1.3.1 Number of subjects for this age range 263
排除标准
- •Subjects are not permitted to enroll in the study if any 1 of the following criteria is met.
- •1.Subject has previously participated in this study.
- •2.Subject has participated in another study of an investigational medicinal product (IMP) or a medical device within the last 30 days or is currently participating in another study of an IMP or medical device.
- •3.Subject has an atypical parkinsonian syndrome or secondary parkinsonism (e.g., due to drugs, toxins, metabolic disorders, encephalitis, cerebrovascular disease or degenerative disease).
- •4.Subject has a history of psychosis or hallucinations within the previous 12 months.
- •5.Subject has cognitive impairment in the judgment of the Investigator that excludes him/her from understanding consent or participating in the study.
- •6.Subject has previous exposure to levodopa or a dopamine agonist for longer than 4 weeks; if previous exposure was less than 4 weeks then it must not be within 2 months prior to the baseline visit.
- •7.Subject has previous exposure to a MAO-B inhibitor for longer than 4 weeks; if previous exposure was less than 4 weeks then it must not be within 3 months prior to the baseline visit.
- •8.Subject who has taken anticholinergic drugs for PD or amantadine for longer than 4 weeks; if previous exposure was less than 4 weeks then it must not be within 1 month prior to the baseline visit.
- •9.Subject who is taking non-selective MAO inhibitors.
- •10.Subject who is taking potent CYP1A2 inhibitors, e,g, Ciprofloxacin
- •11.Subject who is taking antitussive agent dextromethorphan.
- •12.Subject who is taking analgesic agents such as tramadol, meperidine, methadone and propoxyphene.
- •13.Subject who is taking strong 3A4 inducers, e.g., St. John's Wort or cyclobenzaprine (tricyclic muscle relaxant).
- •14.Subject who is taking dopamine antagonists, such as the neuroleptics (phenothiazines, butyrophenones, thioxanthenes) or metoclopramide.
- •15.Subject has a history of alcohol or drug abuse or dependence within the prior 12 months, according to Investigator judgment, (alcohol intake is limited to 1 glass or shot per day during the whole study taken not less than 3 hours before or after dosing (see section 10.2).
- •16.Any relevant medical, surgical, or psychiatric condition, laboratory value, or concomitant medication which, in the opinion of the Investigator, makes the subject unsuitable for study entry or potentially unable to complete all aspects of the study.
- •17.Subject has severe renal impairment (creatinine clearance <30 mL/min) or on dialysis.
- •18.Subject has moderate (Child-Pugh categorization B, score 7-9) or severe (Child-Pugh categorization C, score 10-15) hepatic impairment.
- •19.Subject has a lifetime history of suicide attempt (including an active attempt, interrupted attempt or aborted attempt), or has suicidal ideation in the past 6 months as indicated by a positive response ('Yes') to either Question 4 or Question 5 of the Columbia-Suicide Severity Rating Scale (CSSRS) at Screening.
- •20.Subject has known hypersensitivity or intolerance to pramipexole or rasagiline or to any components or excipients of the test drug or placebo.
- •21.Subject who has a history of neuroleptic malignant syndrome.
- •22.Subject who is pregnant or breastfeeding.
- •23.Subject, who, for any reason, is judged by the Investigator or the eligibility monitoring committee (EMC) to be inappropriate for this study, including a subject who is unable to communicate or cooperate with the Investigator or who has/h
研究者
相似试验
进行中（未招募）
1 期
Clinical Efficacy, Safety and Tolerability of P2B001 in Early Parkinson's DiseaseEarly Parkinson's DiseaseMedDRA version: 20.0Level: HLTClassification code 10034005Term: Parkinson's disease and parkinsonismSystem Organ Class: 100000004852EUCTR2017-001420-21-ESPharma Two B Ltd525
进行中（未招募）
不适用
Multinational Clinical Trial of 12 weeks of duration to test the efficacy of a new drug called CHF 1535 50/6 (fixed combination of a corticoteroid and a long-acting Beta 2 agonist) compared to a free combination of the same substances, and to the corticosteroid only in asthmatic childreAsthmaEUCTR2009-016757-18-ITCHIESI1,000
进行中（未招募）
不适用
Multinational Clinical Trial of 12 weeks of duration to test the efficacy of a new drug called CHF 1535 50/6 (fixed combination of a corticoteroid and a long-acting Beta 2 agonist) compared to a free combination of the same substances, and to the corticosteroid only in asthmatic childreMedDRA version: 14.0Level: PTClassification code 10003553Term: AsthmaSystem Organ Class: 10038738 - Respiratory, thoracic and mediastinal disordersAsthmaEUCTR2009-016757-18-HUChesi Farmaceutici SpA700
进行中（未招募）
1 期
Multinational Clinical Trial of 12 weeks of duration to test the efficacy of a new drug called CHF 1535 50/6 (fixed combination of a corticoteroid and a long-acting Beta 2 agonist) compared to a free combination of the same substances, and to the corticosteroid only in asthmatic childreAsthmaMedDRA version: 14.0Level: PTClassification code 10003553Term: AsthmaSystem Organ Class: 10038738 - Respiratory, thoracic and mediastinal disordersEUCTR2009-016757-18-SKChesi Farmaceutici SpA700
进行中（未招募）
不适用
Multinational Clinical Trial of 12 weeks of duration to test the efficacy of a new drug called CHF 1535 50/6 (fixed combination of a corticoteroid and a long-acting Beta 2 agonist) compared to a free combination of the same substances, and to the corticosteroid only in asthmatic childreasthmaEUCTR2009-016757-18-Outside-EU/EEAChiesi Farmaceutici SpA700